Canaccord Genuity Maintains Buy on Health Catalyst, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Richard Close maintains a Buy rating on Health Catalyst (NASDAQ:HCAT) with a price target of $11.
May 21, 2024 | 7:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Richard Close maintains a Buy rating on Health Catalyst with a price target of $11, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target of $11 by a reputable analyst suggests positive sentiment and confidence in Health Catalyst's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100